CD19 and acute lymphoblastic leukemia: The frequencies of human CD19+ B-ALL cells in the peripheral blood, bone marrow, and spleen were reduced in the combined treatment group compared to the vehicle or monotherapy groups (Fig. 2F, G and S2H, I).